title: Treatment of tuberculosis: present status and future prospects.
abstract: Over recent years, tuberculosis (TB) and disease caused by human immunodeficiency virus (HIV) have merged in a synergistic pandemic. The number of new cases of TB is stabilizing and declining, except in countries with a high prevalence of HIV infection. In these countries, where HIV is driving an increase in the TB burden, the capacity of the current tools and strategies to reduce the burden has been exceeded. This paper summarizes the current status of TB management and describes recent thinking and strategy adjustments required for the control of TB in settings of high HIV prevalence. We review the information on anti-TB drugs that is available in the public domain and highlight the need for continued and concerted efforts (including financial, human and infrastructural investments) for the development of new strategies and anti-TB agents.
authors.affiliation: UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in TropicalDiseases (TDR), Centre Casai, Geneva, Switzerland. onyebujohp@who.int
authors.forename: Philip
authors.initials: P
authors.lastname: Onyebujoh
authors.forename: Alimuddin
authors.initials: A
authors.lastname: Zumla
authors.forename: Isabella
authors.initials: I
authors.lastname: Ribeiro
authors.forename: Roxana
authors.initials: R
authors.lastname: Rustomjee
authors.forename: Peter
authors.initials: P
authors.lastname: Mwaba
authors.forename: Melba
authors.initials: M
authors.lastname: Gomes
authors.forename: John M
authors.initials: JM
authors.lastname: Grange
mesh_terms: D000995:Antitubercular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002985:Clinical Protocols; D015658:HIV Infections / Q000150:complications; D006801:Humans; D011634:Public Health; D014376:Tuberculosis / Q000188:drug therapy* / Q000209:etiology
chemical_list: D000995:Antitubercular Agents